TGA — authorised 30 May 2020
- Marketing authorisation holder: Sanofi-Aventis groupe
- Status: approved
🇦🇺 Hu38Sb19 in Australia
TGA authorised Hu38Sb19 on 30 May 2020
Marketing authorisation
Hu38Sb19 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Australia
Frequently asked questions
Is Hu38Sb19 approved in Australia?
Yes. TGA authorised it on 30 May 2020.
Who is the marketing authorisation holder for Hu38Sb19 in Australia?
Sanofi-Aventis groupe holds the Australian marketing authorisation.